Augmentation of Cardiac Contractility Mediated by the Human &bgr;3-Adrenergic Receptor Overexpressed in the Hearts of Transgenic Mice

Background—Stimulation of &bgr;1- and &bgr;2-adrenergic receptors (ARs) in the heart results in positive inotropy. In contrast, it has been reported that the &bgr;3AR is also expressed in the human heart and that its stimulation leads to negative inotropic effects. Methods and Results—To better understand the role of &bgr;3ARs in cardiac function, we generated transgenic mice with cardiac-specific overexpression of 330 fmol/mg protein of the human &bgr;3AR (TG&bgr;3 mice). Hemodynamic characterization was performed by cardiac catheterization in closed-chest anesthetized mice, by pressure-volume-loop analysis, and by echocardiography in conscious mice. After propranolol blockade of endogenous &bgr;1- and &bgr;2ARs, isoproterenol resulted in an increase in contractility in the TG&bgr;3 mice (30%), with no effect in wild-type mice. Similarly, stimulation with the selective human &bgr;3AR agonist L-755,507 significantly increased contractility in the TG&bgr;3 mice (160%), with no effect in wild-type mice, as determined by hemodynamic measurements and by end-systolic pressure-volume relations. The underlying mechanism of the positive inotropy incurred with L-755,507 in the TG&bgr;3 mice was investigated in terms of &bgr;3AR–G-protein coupling and adenylyl cyclase activation. Stimulation of cardiac membranes from TG&bgr;3 mice with L-755,507 resulted in a pertussis toxin–insensitive 1.33-fold increase in [35S]GTP&ggr;S loading and a 1.6-fold increase in adenylyl cyclase activity. Conclusions—Cardiac overexpression of human &bgr;3ARs results in positive inotropy only on stimulation with a &bgr;3AR agonist. Overexpressed &bgr;3ARs couple to Gs and activate adenylyl cyclase on agonist stimulation.

[1]  Marc G. Caron,et al.  Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice* , 1998, The Journal of Biological Chemistry.

[2]  Ellson Y. Chen,et al.  Overview of manual and automated DNA sequencing by the dideoxy chain termination method , 1991 .

[3]  F. Lönnqvist,et al.  Tissue distribution of beta 3-adrenergic receptor mRNA in man. , 1993, The Journal of clinical investigation.

[4]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[5]  S. Vatner,et al.  Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. , 1996, The Journal of pharmacology and experimental therapeutics.

[6]  D. Hoyer,et al.  (+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. , 1981, Naunyn-Schmiedeberg's archives of pharmacology.

[7]  T. Nakano,et al.  The negative inotropic effect of beta3-adrenoceptor stimulation in the beating guinea pig heart. , 2000, Journal of cardiovascular pharmacology.

[8]  R. Lefkowitz,et al.  Enhanced Myocardial Function inTransgenic Mice Overexpressing theP2-Adrenergic Receptor , 1994 .

[9]  K. Higashi,et al.  Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells. , 1999, Biochemical pharmacology.

[10]  R. A. Johnson,et al.  Assay of adenylyl cyclase catalytic activity. , 1991, Methods in enzymology.

[11]  J. Montastruc,et al.  Peripheral cardiovascular actions of SR 58611 A, a beta 3‐adrenoceptor agonist, in the dog: lack of central effect , 1999, Fundamental & clinical pharmacology.

[12]  S. Liggett,et al.  Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Strosberg Structure and function of the beta 3-adrenergic receptor. , 1997, Annual review of pharmacology and toxicology.

[14]  北村 哲也 The Negative Inotropic Effect of β3-Adrenoceptor Stimulation in the Beating Guinea Pig Heart , 2000 .

[15]  J. Hare,et al.  beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. , 2000, The Journal of clinical investigation.

[16]  D. Bernstein,et al.  Cardiovascular and Metabolic Alterations in Mice Lacking Both β1- and β2-Adrenergic Receptors* , 1999, The Journal of Biological Chemistry.

[17]  F. Charpentier,et al.  Functional beta3-adrenoceptor in the human heart. , 1996, The Journal of clinical investigation.

[18]  A. Strosberg STRUCTURE AND FUNCTION OF THE 3 -ADRENERGIC RECEPTOR , 1997 .

[19]  P. Gazzotti,et al.  Purification and Reconstitution of the Ca2+-Pumping ATPase of Red Blood Cells , 1994 .

[20]  A. Strosberg,et al.  Molecular characterization of the human beta 3-adrenergic receptor. , 1989, Science.

[21]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[22]  W. Lederer,et al.  Cellular and functional defects in a mouse model of heart failure. , 2000, American journal of physiology. Heart and circulatory physiology.

[23]  T. Wieland,et al.  Measurement of receptor-stimulated guanosine 5'-O-(gamma-thio)triphosphate binding by G proteins. , 1994, Methods in enzymology.

[24]  L. Luttrell,et al.  The β3-Adrenergic Receptor Activates Mitogen-activated Protein Kinase in Adipocytes through a Gi-dependent Mechanism* , 1999, The Journal of Biological Chemistry.

[25]  A. Strosberg,et al.  Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation. , 1999, Molecular pharmacology.

[26]  R. Fremeau,et al.  Distribution of β3-adrenoceptor mRNA in human tissues , 1995 .

[27]  M. Bristow Why does the myocardium fail? Insights from basic science , 1998, The Lancet.

[28]  R. Miller,et al.  A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. , 1998, The Journal of clinical investigation.

[29]  C. Gauthier,et al.  Beta 3‐adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium‐derived nitric oxide in rat thoracic aorta , 1999, British journal of pharmacology.

[30]  B. Lowell,et al.  Targeted Disruption of the β3-Adrenergic Receptor Gene * , 1995, The Journal of Biological Chemistry.